Discovery and optimization of a series of 3-substituted indazole derivatives as multi-target kinase inhibitors for the treatment of lung squamous cell carcinoma
Authors:
- 1 February 2019
- journal article
- research article
- Published by Elsevier in European Journal of Medicinal Chemistry
- Vol. 163, 671-689
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81330076, 81773762)
- Personalized Medicines—Molecular Signature-based Drug Discovery and Development
- Chinese Academy of Sciences (XDA12020323)
- National Science & Technology
- “Key New Drug Creation and Manufacturing Program” of China (2018ZX09711002-004)
This publication has 17 references indexed in Scilit:
- The 2015 World Health Organization Classification of Lung TumorsJournal of Thoracic Oncology, 2015
- Introduction to The 2015 World Health Organization Classification of Tumors of the Lung, Pleura, Thymus, and HeartJournal of Thoracic Oncology, 2015
- Adaptive Responses to Dasatinib-Treated Lung Squamous Cell Cancer Cells Harboring DDR2 MutationsCancer Research, 2014
- Discoidin Domain Receptor 2 Signaling Networks and Therapy in Lung CancerJournal of Thoracic Oncology, 2014
- Prognostic role of FGFR1 amplification in early-stage non-small cell lung cancerBritish Journal of Cancer, 2014
- Personalized therapy on the horizon for squamous cell carcinoma of the lungLung Cancer, 2013
- Discoidin Domain Receptors: Unique Receptor Tyrosine Kinases in Collagen-mediated SignalingJournal of Biological Chemistry, 2013
- Identification of Enriched Driver Gene Alterations in Subgroups of Non-Small Cell Lung Cancer Patients Based on Histology and Smoking StatusPLOS ONE, 2012
- Discoidin domain receptor 2 is a critical regulator of epithelial–mesenchymal transitionMatrix Biology, 2011
- Fibroblast growth factor signalling: from development to cancerNature Reviews Cancer, 2010